lung cancer
Conditions
Interventions
Bevacizumab (Chugai Pharmaceutical Co. Ltd.,: Avastin) S-1 (Taiho pharmaceutical Co. Ltd., TS-1)
Sponsors
Shinshu University thoracic surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with cytological or histological diagnosis of NSCLC except squamous cell carcinoma. Patients who have postoperative recurrence, refractory to one chemotherapy regimen. Preoperative or postoperative adjuvant chemotherapy is not considered as one regimen. Patience with Measurable lesion based on RECIST ver1.1. A lesion within a radiation site is excluded from a measurable lesion. Pleural effusion after pleurodesis is not considered as non-target lesion. Patients who have 4 weeks or more after the prior chemotherapy. If the patient underwent therapy, there should be the following interval between the therapy and the registration. Radiotherapy other than thoracic radiation one week. Radiotherapy including pulmonary field 3 months. Surgery, except CV-port reservation 4 weeks Thoracic drainage two weeks Open biopsy, treatment of injury two weeks Aspiration biopsy, CV-port reservation one week Age: 20 years old or older ECOG Performance Status (PS); 0-2
Exclusion criteria
Exclusion criteria: Besides the above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and efficacy | — |
Countries
Japan
Contacts
Public ContactTakayuki Shiina
shinshu University thoracic surgery
Outcome results
None listed